Retirement Systems of Alabama Sells 7,120 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Retirement Systems of Alabama decreased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 2.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 274,616 shares of the biopharmaceutical company’s stock after selling 7,120 shares during the quarter. Retirement Systems of Alabama’s holdings in Gilead Sciences were worth $22,247,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Nilsine Partners LLC lifted its stake in shares of Gilead Sciences by 1.1% in the 3rd quarter. Nilsine Partners LLC now owns 11,894 shares of the biopharmaceutical company’s stock valued at $891,000 after purchasing an additional 127 shares during the period. Etesian Wealth Advisors Inc. lifted its stake in Gilead Sciences by 0.7% in the fourth quarter. Etesian Wealth Advisors Inc. now owns 18,318 shares of the biopharmaceutical company’s stock valued at $1,486,000 after buying an additional 128 shares during the period. Financial Counselors Inc. boosted its holdings in Gilead Sciences by 1.5% during the fourth quarter. Financial Counselors Inc. now owns 8,862 shares of the biopharmaceutical company’s stock worth $718,000 after buying an additional 128 shares during the last quarter. Revolve Wealth Partners LLC boosted its holdings in Gilead Sciences by 3.7% during the fourth quarter. Revolve Wealth Partners LLC now owns 3,607 shares of the biopharmaceutical company’s stock worth $292,000 after buying an additional 130 shares during the last quarter. Finally, Institutional & Family Asset Management LLC grew its position in shares of Gilead Sciences by 10.3% during the 3rd quarter. Institutional & Family Asset Management LLC now owns 1,501 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 140 shares during the period. 83.67% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of brokerages recently weighed in on GILD. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a research report on Friday. Barclays decreased their price target on shares of Gilead Sciences from $80.00 to $76.00 and set an “equal weight” rating for the company in a report on Monday. Cantor Fitzgerald dropped their price objective on Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 7th. Truist Financial cut Gilead Sciences from a “buy” rating to a “hold” rating and decreased their target price for the company from $91.00 to $82.00 in a research note on Thursday, February 22nd. Finally, Oppenheimer reaffirmed an “outperform” rating and set a $105.00 price target on shares of Gilead Sciences in a research report on Friday, April 19th. Eleven equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $83.60.

Gilead Sciences Trading Up 0.8 %

Gilead Sciences stock opened at $65.94 on Tuesday. The company has a debt-to-equity ratio of 1.08, a current ratio of 0.98 and a quick ratio of 0.72. The firm has a 50-day moving average of $71.16 and a 200-day moving average of $76.17. The company has a market cap of $82.10 billion, a price-to-earnings ratio of 183.17, a P/E/G ratio of 1.29 and a beta of 0.19. Gilead Sciences, Inc. has a one year low of $64.63 and a one year high of $87.86.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.49) by $0.17. The business had revenue of $6.69 billion for the quarter, compared to the consensus estimate of $6.36 billion. Gilead Sciences had a net margin of 1.76% and a return on equity of 24.34%. The firm’s revenue for the quarter was up 5.3% on a year-over-year basis. During the same period in the previous year, the company earned $1.37 earnings per share. On average, equities analysts expect that Gilead Sciences, Inc. will post 3.82 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, June 27th. Investors of record on Friday, June 14th will be paid a $0.77 dividend. The ex-dividend date of this dividend is Friday, June 14th. This represents a $3.08 annualized dividend and a yield of 4.67%. Gilead Sciences’s dividend payout ratio (DPR) is currently 855.56%.

Insiders Place Their Bets

In other news, insider Merdad Parsey sold 2,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $73.18, for a total value of $146,360.00. Following the completion of the sale, the insider now directly owns 100,936 shares of the company’s stock, valued at $7,386,496.48. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 0.29% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.